[Complete and permanent regression of persistent uveitic cystoid macular edema after single intravitreal iniection of aflibercept in patient previously treated with multiple intravitreal injections of ranibizumab and bevacizumab].
A case report of a twenty-year-old man with quiescent, idiopathic intermediate uveitis in his right eye treated with systemic corticosteroids and persistent cystoid macular edema, admitted for further treatment due to chronic reduction in visual acuity, is presented. A therapy involving intravitreal injections of ranibizumab (Lucentis), followed by bevacizumab (Avastin) was started, leading to transient improvement of visual acuity and edema reduction confirmed in optical coherent tomography. A de cision of switching to intravitreal aflibercept (Eylea) was made. After a single intravitreal injection of aflibercept, a complete and sustained resolution of macular edema was achieved. aflibercept, uveitis, cystoid macular edema.
Marcin
M
Swituła
D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000068258:Bevacizumab; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006801:Humans; D056965:Injections, Intraocular; D008269:Macular Edema / Q000150:complications / Q000188:drug therapy*; D008297:Male; D000069579:Ranibizumab; D040262:Receptors, Vascular Endothelial Growth Factor / Q000008:administration & dosage*; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage*; D012074:Remission Induction; D016896:Treatment Outcome; D014792:Visual Acuity / Q000187:drug effects*; D055815:Young Adult
D061067:Antibodies, Monoclonal, Humanized; D011993:Recombinant Fusion Proteins; C533178:aflibercept; D000068258:Bevacizumab; D040262:Receptors, Vascular Endothelial Growth Factor; D000069579:Ranibizumab